MEI Pharma Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
LITS$0.96+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| For the Nine Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $36,184 | $(21,809) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Change in fair value of warrant liability | — | (1,603) |
| Share-based compensation | 1,881 | 3,290 |
| Issuance of warrants | — | 500 |
| Noncash lease expense | 1,136 | 1,063 |
| Depreciation expense | 258 | 288 |
| Changes in operating assets and liabilities: | ||
| Unbilled receivables | 85 | 5,464 |
| Prepaid expenses and other current assets | 4,144 | (37) |
| Accounts payable | (3,166) | (3,529) |
| Accrued liabilities | (7,073) | 5,444 |
| Deferred revenue | (64,862) | (29,316) |
| Operating lease liability | (1,061) | (937) |
| Net cash used in operating activities | (32,474) | (41,182) |
| Cash flows from investing activities: | ||
| Purchases of short-term investments | (58,232) | (92,098) |
| Proceeds from maturity of short-term investments | 87,835 | 126,386 |
| Proceeds from the sale of property and equipment | — | 6 |
| Purchases of property and equipment | (7) | — |
| Net cash provided by investing activities | 29,596 | 34,294 |
| Cash flows from financing activities: | ||
| Payments of tax withholdings related to vesting of restricted stock units | — | (40) |
| Payment of cash dividend | (11,660) | — |
| Net cash used in financing activities | (11,660) | (40) |
| Net decrease in cash and cash equivalents | (14,538) | (6,928) |
| Cash and cash equivalents at beginning of the period | 16,906 | 15,740 |
| Cash and cash equivalents at end of the period | $2,368 | $8,812 |
| Supplemental cash flow information: | ||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $— | $4,347 |
| Financing costs included in accounts payable | $208 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.